2018-21: A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL)
Investigator Initiated Research
Inclusion open since 1-3-2019
This study is designed to evaluate the efficacy and safety of
brolucizumab in treatment of patients with visual impairment due to
diabetic macular edema (DME).